Leronlimab as use for immune activation in HIV may also be needed to counter the very drugs currently used in ART treatment.

Quote:

---

New antiretrovirals are not completely free from short- and long-term toxicities. For instance, mitochondrial dysfunction is a known effect of long-term exposure to ART and occurs independently of that caused by HIV infection itself. Current antiretrovirals are considered to have significantly less mitochondrial toxicity, but still produce some toxicity in specific cell types, potentially contributing to neurocognitive disorders and cardiovascular risk.

The mechanisms by which antiretrovirals can contribute to ageing are probably multifactorial, but some toxicities have been well described for certain classes of antiretrovirals. Tenofovir disoproxil difumarate is associated with bone and kidney toxicities, and abacavir with cardiovascular risk. Boosted protease inhibitors cause metabolic toxicities, such as insulin resistance or dyslipidemia and produce senescence in endothelial arterial cells. Integrase inhibitors have been linked to weight gain and neuropsyquiatric symptoms
https://www.thelancet.com/journals/ebiom/arti...9/fulltext

---